Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds.

@article{Vaquero2013ActivationOT,
  title={Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds.},
  author={Javier Vaquero and {\'O}scar Briz and Elisa Herraez and Jordi Muntan{\'e} and Jose J G Marin},
  journal={Biochimica et biophysica acta},
  year={2013},
  volume={1833 10},
  pages={2212-9}
}
The success of pharmacological treatments in primary liver cancers is limited by the marked efficacy of mechanisms of chemoresistance already present in hepatocytes. The role of the nuclear receptor FXR is unclear. Although, in non-treated liver tumors, its expression is reduced, the refractoriness to anticancer drugs is high. Moreover, the treatment with cisplatin up-regulates FXR. The aim of this study was to investigate whether FXR is involved in stimulating chemoprotection/chemoresistance… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Synergy of Raddeanin A and cisplatin induced therapeutic effect enhancement in human hepatocellular carcinoma.

J Z Li, Ye Yu, +3 authors Ji-Yu Gong
Biochemical and biophysical research communications • 2017
View 1 Excerpt

Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?

Annual review of pharmacology and toxicology • 2016
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 44 references

D

E. P. Cuesta, C. Langhi
Haro, P.F. Marrero, J.C. Rodriguez, Transcription elongation factor TFIIS.1 gene is regulated by farnesoid X receptor, FEBS J. 279 • 2012
View 2 Excerpts

C

R. I. Macias
Hierro, S.C. de Juan, F. Jimenez, F. Gonzalez-San Martin, J.J. Marin, Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases, Br. J. Nutr. 106 • 2011
View 2 Excerpts

L

M. I. Diaz Bessone, D. E. Berardi, P. B. Campodonico, L. B. Todaro
Lothstein, E.D. Bal de Kier Joffe, A.J. Urtreger, Involvement of PKC delta (PKCdelta) in the resistance against different doxorubicin analogs, Breast Cancer Res. Treat. 126 • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…